Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000.

Blood (2007) 110 (11): 1425.

https://doi.org/10.1182/blood.V110.11.1425.1425

Published: 2007

Journal Articles

Risk-Adjusted Therapy of Acute Lymphoblastic Leukemia Can Decrease Treatment Burden and Improve Survival: Treatment Results of 2169 Unselected Pediatric and Adolescent Patients Enrolled in the Trial ALL-BFM 95.

Anja Möricke, MD, Alfred Reiter, MD, Martin Zimmermann, PhD, Helmut Gadner, MD, Martin Stanulla, MD, Wolf-Dieter Ludwig, MD, Jochen Harbott, PhD, Georg Mann, MD, Felix Niggli, MD, Günter Henze, MD, Karl Welte, MD, Thomas Klingebiel, MD, Charlotte Niemeyer, MD, Felix Zintl, MD, Hansjörg Riehm, MD, Martin Schrappe, MD

Blood (2007) 110 (11): 584.

https://doi.org/10.1182/blood.V110.11.584.584

Published: 2007

Journal Articles

Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Acute Lymphoblastic Leukemia (ALL) According to WBC Count, Age and TEL/AML1 Status at Diagnosis. Results of the AIEOP-BFM ALL 2000 Study.

Valentino Conter, MD, André Schrauder, MD, Helmut Gadner, MD, Maria Grazia Valsecchi, PhD, Martin Zimmermann, PhD, Michael Dvorzak, MD, Andrea Biondi, MD, Claus R. Bartram, PhD, Giuseppe Basso, MD, Martin Stanulla, MD, Maurizio Aricò, MD, Karl Welte, MD, Giuseppe Masera, MD, Martin Schrappe, MD

Blood (2007) 110 (11): 544.

https://doi.org/10.1182/blood.V110.11.544.544

Published: 2007

Journal Articles

BIOV-111 a European Phase II Trial of Clofarabine (Evoltra ® ) in Refractory and Relapsed Childhood Acute Lymphoblastic Leukemia.

Pamela Kearns, MD,PhD, Gerard Michel, MD, Brigitte Nelken, MD, Simon Joel, PhD, Essam Al-Ghazaly, MD, Auke Beishuizen, MD,PhD, Valentino Conter, MD, Helmut Gadner, MD, Gunter Henze, MD, Hazel Smith, PhD, Andre Baruchel, MD, Vaskar Saha, MD, PhD

Blood (2006) 108 (11): 1859.

https://doi.org/10.1182/blood.V108.11.1859.1859

Published: 2006

Journal Articles

Results in Children and Adolescents Treated According to Study AML-BFM 98: Less Toxic Deaths in the Short-Cycle Arm Than in the 6-Week Consolidation Arm.

Ursula Creutzig, MD, Reinhardt Dirk, MD, Joerg Ritter, MD, Norbert Graf, MD, Johannes Herrmann, MD, Thomas Klingebiel, MD, Alfred Reiter, MD, Helmut Gadner, MD, Felix Niggli, MD, Jan Stary, MD, Martin Zimmermann, PhD

Blood (2005) 106 (11): 274.

https://doi.org/10.1182/blood.V106.11.274.274

Published: 2005

Journal Articles

Treatment Response and Outcome in Childhood t(1;19)/ TCF3-PBX1 Positive Acute Lymphoblastic Leukemia: A Report from the Austrian BFM Group.

Leo Kager, MD, Thomas Lion, MD, PhD, Andishe Attarbaschi, MD, Margit Koenig, PhD, Sabine Strehl, PhD, Oskar A. Haas, MD, Michael N. Dworzak, MD, Martin Schrappe, MD, PhD, Helmut Gadner, MD, Georg Mann, MD

Blood (2005) 106 (11): 1458.

https://doi.org/10.1182/blood.V106.11.1458.1458

Published: 2005

Journal Articles

Prognostic Factors in CD10 Negative Precursor B-Cell Acute Lymphoblastic Leukemia in Children: Data from Three Consecutive Trials ALL-BFM 86, 90, and 95.

Anja Möricke, MD, Richard Ratei, MD, Wolf-Dieter Ludwig, MD, PhD, Jochen Harbott, PhD, Arndt Borkhardt, MD, PhD, Susanne Viehmann, PhD, Martin Zimmermann, PhD, Helmut Gadner, MD, PhD, Hansjörg Riehm, MD, PhD, Martin Schrappe, MD, PhD

Blood (2004) 104 (11): 1957.

https://doi.org/10.1182/blood.V104.11.1957.1957

Published: 2004

Journal Articles

Pcr-Screening for Viral Infections during Allogeneic Stem Cell Transplantation: Clinical Benefit and Economic Consideration.

Susanne Matthes-Martin, MD, Thomas Lion, MD PhD, Anita Lawitschka, MD, Brigitta Keck, MD, Susanne Karlhuber, MD, Helmut Gadner, MD, Christina Peters, MD

Blood (2004) 104 (11): 2240.

https://doi.org/10.1182/blood.V104.11.2240.2240

Published: 2004

Journal Articles

Chronic Myeloid Leukemia (CML) in Childhood - Results of the Multicenter-Trial CML-paed.

Meinolf Suttorp, MD, Alexander Claviez, MD, Yvonne Martiniak, Thomas Klingebiel, MD, Dietrich Niethammer, MD, Helmut Gadner, MD, Chris Peters, MD, Hartmut Kabisch, MD, Bernhard Kremens, MD, Felix Zintl, MD, Guenter Henze, MD, Ulrich Goebel, MD

Blood (2004) 104 (11): 617.

https://doi.org/10.1182/blood.V104.11.617.617

Published: 2004

NARROW

Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000.

Risk-Adjusted Therapy of Acute Lymphoblastic Leukemia Can Decrease Treatment Burden and Improve Survival: Treatment Results of 2169 Unselected Pediatric and Adolescent Patients Enrolled in the Trial ALL-BFM 95.

Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Acute Lymphoblastic Leukemia (ALL) According to WBC Count, Age and TEL/AML1 Status at Diagnosis. Results of the AIEOP-BFM ALL 2000 Study.

BIOV-111 a European Phase II Trial of Clofarabine (Evoltra ® ) in Refractory and Relapsed Childhood Acute Lymphoblastic Leukemia.

Results in Children and Adolescents Treated According to Study AML-BFM 98: Less Toxic Deaths in the Short-Cycle Arm Than in the 6-Week Consolidation Arm.

Treatment Response and Outcome in Childhood t(1;19)/ TCF3-PBX1 Positive Acute Lymphoblastic Leukemia: A Report from the Austrian BFM Group.

Prognostic Factors in CD10 Negative Precursor B-Cell Acute Lymphoblastic Leukemia in Children: Data from Three Consecutive Trials ALL-BFM 86, 90, and 95.

Pcr-Screening for Viral Infections during Allogeneic Stem Cell Transplantation: Clinical Benefit and Economic Consideration.

Chronic Myeloid Leukemia (CML) in Childhood - Results of the Multicenter-Trial CML-paed.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only